These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16266284)

  • 21. Management of moderate to severe Alzheimer's disease: focus on memantine.
    Dominguez E; Chin TY; Chen CP; Wu TY
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM; Boyle LL; Porsteinsson AP
    Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cholesterol inhibitor and memantine in symptomatic dementia therapy].
    Rodda J; Carter J
    Praxis (Bern 1994); 2013 Feb; 102(5):293-300; discussion 298-9. PubMed ID: 23446240
    [No Abstract]   [Full Text] [Related]  

  • 27. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the rationale for new treatment strategies in Alzheimer's disease?
    Rogawski MA
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia.
    Möbius HJ
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S172-8. PubMed ID: 10609698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memantine: pharmacological properties and clinical uses.
    Kumar S
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.
    Majláth Z; Török N; Toldi J; Vécsei L
    Curr Neuropharmacol; 2016; 14(2):200-9. PubMed ID: 26564141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.
    Yang JC; Niu YQ; Simon C; Seritan AL; Chen L; Schneider A; Moghaddam ST; Hagerman PJ; Hagerman RJ; Olichney JM
    Neuropsychopharmacology; 2014 Nov; 39(12):2760-8. PubMed ID: 24871547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
    Gallarda T; Lôo H
    Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
    Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Memantine (Namenda) for moderate to severe Alzheimer's disease.
    Ables AZ
    Am Fam Physician; 2004 Mar; 69(6):1491-2. PubMed ID: 15053415
    [No Abstract]   [Full Text] [Related]  

  • 40. Memantine in neurological disorders - schizophrenia and depression.
    Czarnecka K; Chuchmacz J; Wójtowicz P; Szymański P
    J Mol Med (Berl); 2021 Mar; 99(3):327-334. PubMed ID: 33447926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.